Merck & Co., Inc. (MRK) Stock Price, News & Analysis

Company Overview

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Key Stats

• Today's Range: $84.60 to $87.32
• 50-Day Range: $78.17 to $86.06
• 52-Week Range: $73.31 to $120.30
• Volume: 13.71 million shs
• Average Volume: 11.85 million shs
• Market Capitalization: $214.96 billion
• P/E Ratio: 13.26
• Dividend Yield: 3.76%
• Price Target: $107.44
• Consensus Rating: Hold

Merck & Co., Inc. Stock Analysis - MarketRank™

Merck & Co., Inc. scored higher than 99% of companies evaluated by MarketBeat, and ranked 3rd out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

Merck & Co., Inc. has received a consensus rating of Hold. The company's average rating score is 2.35, and is based on 6 buy ratings, 12 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Merck & Co., Inc. has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.8 / 5
• Proj. Earnings Growth: 9.88%

Earnings Growth

Earnings for Merck & Co., Inc. are expected to grow by 9.88% in the coming year, from $9.01 to $9.90 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Merck & Co., Inc. is 13.26, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.08.

Price to Earnings Ratio vs. Sector

The P/E ratio of Merck & Co., Inc. is 13.26, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 30.40.

Price to Earnings Growth Ratio

Merck & Co., Inc. has a PEG Ratio of 0.89. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Merck & Co., Inc. has a P/B Ratio of 4.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.04% of the float of Merck & Co., Inc. has been sold short.

Short Interest Ratio / Days to Cover

Merck & Co., Inc. has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Merck & Co., Inc. has recently decreased by 10.05%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 5.0 / 5
• Dividend Strength: Strong

Dividend Leadership

Merck & Co., Inc. is a leading dividend payer. It pays a dividend yield of 3.83%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Merck & Co., Inc. has been increasing its dividend for 14 years.

Dividend Coverage

The dividend payout ratio of Merck & Co., Inc. is 49.92%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Merck & Co., Inc. will have a dividend payout ratio of 32.73% next year. This indicates that Merck & Co., Inc. will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -2.49

Percentage of Shares Shorted

1.04% of the float of Merck & Co., Inc. has been sold short.

Short Interest Ratio / Days to Cover

Merck & Co., Inc. has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Merck & Co., Inc. has recently decreased by 10.05%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.39

News Sentiment

Merck & Co., Inc. has a news sentiment score of 1.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 69 news articles for Merck & Co., Inc. this week, compared to 76 articles on an average week.

Search Interest

Only 117 people have searched for MRK on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.

MarketBeat Follows

41 people have added Merck & Co., Inc. to their MarketBeat watchlist in the last 30 days. This is an increase of 52% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Merck & Co., Inc. insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.13% of the stock of Merck & Co., Inc. is held by insiders.

Percentage Held by Institutions

76.07% of the stock of Merck & Co., Inc. is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MRK Stock Analysis - Frequently Asked Questions

How have MRK shares performed this year?

Merck & Co., Inc.'s stock was trading at $99.48 at the start of the year. Since then, MRK stock has decreased by 13.5% and is now trading at $86.06.

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) issued its earnings results on Tuesday, July, 29th. The company reported $2.13 EPS for the quarter, beating analysts' consensus estimates of $2.03 by $0.10. The company had revenue of $15.81 billion for the quarter, compared to the consensus estimate of $15.92 billion. Merck & Co., Inc. had a net margin of 25.79% and a trailing twelve-month return on equity of 41.05%.
Read the conference call transcript.

Is Merck & Co., Inc. buying back stock?

Merck & Co., Inc.'s Board of Directors authorized a stock repurchase program on Tuesday, January 28th 2025, which authorizes the company to buy back $10,000,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 4.1% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's board of directors believes its stock is undervalued.

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s top institutional shareholders include Vanguard Group Inc. (10.13%), State Street Corp (4.74%), Geode Capital Management LLC (2.36%) and Charles Schwab Investment Management Inc. (2.16%). Insiders that own company stock include Kenneth C Frazier, Robert M Davis, Richard R Deluca, Rita A Karachun, Steven Mizell, Joseph Romanelli, Johannes Jacobus Oosthuizen, Dalton E Smart III, Cristal N Downing, Inge G Thulin and Sanat Chattopadhyay.
View institutional ownership trends.

How do I buy shares of Merck & Co., Inc.?

Shares of MRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Merck & Co., Inc. own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Merck & Co., Inc. investors own include Chevron (CVX), Salesforce (CRM), Bristol Myers Squibb (BMY), Comcast (CMCSA), Johnson & Johnson (JNJ), AbbVie (ABBV) and Home Depot (HD).

Company Calendar

• Record date for 7/8 Dividend: 6/16/2025
• Ex-Dividend for 7/8 Dividend: 6/16/2025
• Dividend Payable: 7/08/2025
• Last Earnings: 7/29/2025
• Today: 8/21/2025
• Record date for 10/7 Dividend: 9/15/2025
• Ex-Dividend for 10/7 Dividend: 9/15/2025
• Dividend Payable: 10/07/2025
• Next Earnings (Estimated): 10/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Large Cap Pharma
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:MRK
• CIK: 310158
• Web: www.merck.com
• Phone: (908) 740-4000
• Fax: 908-735-1253
• Employees: 75,000
• Year Founded: 1891

Price Target and Rating

• Average Price Target for Merck & Co., Inc.: $107.44
• High Price Target: $140.00
• Low Price Target: $84.00
• Potential Upside/Downside: +24.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.35
• Research Coverage: 20 Analysts

Profitability

• EPS (Trailing Twelve Months): $6.49
• Trailing P/E Ratio: 13.26
• Forward P/E Ratio: 9.55
• P/E Growth: 0.89
• Net Income: $17.12 billion
• Net Margins: 25.79%
• Pretax Margin: 30.12%
• Return on Equity: 41.05%
• Return on Assets: 16.55%

Debt

• Debt-to-Equity Ratio: 0.69
• Current Ratio: 1.42
• Quick Ratio: 1.17

Sales & Book Value

• Annual Sales: $64.17 billion
• Price / Sales: 3.35
• Cash Flow: $9.63 per share
• Price / Cash Flow: 8.94
• Book Value: $19.64 per share
• Price / Book: 4.38

Miscellaneous

• Outstanding Shares: 2,497,780,000
• Free Float: 2,494,536,000
• Market Cap: $214.96 billion
• Optionable: Optionable
• Beta: 0.38